相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
Silvio E. Inzucchi et al.
DIABETOLOGIA (2015)
Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes
Andre J. Scheen
EXPERT OPINION ON DRUG SAFETY (2015)
Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy: A Randomized Double-Blind Trial of Saxagliptin Plus Dapagliflozin Addition Versus Single Addition of Saxagliptin or Dapagliflozin to Metformin
Julio Rosenstock et al.
DIABETES CARE (2015)
Pharmacodynamics, Efficacy and Safety of Sodium-Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
Andre J. Scheen
DRUGS (2015)
A review of gliptins for 2014
Andre J. Scheen
EXPERT OPINION ON PHARMACOTHERAPY (2015)
Dipeptidyl peptidase IV inhibitor lowers PPARγ agonist-induced body weight gain by affecting food intake, fat mass, and beige/brown fat but not fluid retention
Takahiro Masuda et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2014)
Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis
Richard M. Turner et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial
Benjamin M. Scirica et al.
CIRCULATION (2014)
Hepatotoxicity of Alogliptin
Elizabeth Barbehenn et al.
CLINICAL PHARMACOKINETICS (2014)
Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus
Andre J. Scheen
CLINICAL PHARMACOKINETICS (2014)
Alogliptin: Concern About Hepatotoxicity?
Andre J. Scheen
CLINICAL PHARMACOKINETICS (2014)
Glucuronidation Converts Clopidogrel to a Strong Time-Dependent Inhibitor of CYP2C8: A Phase II Metabolite as a Perpetrator of Drug-Drug Interactions
A. Tornio et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Beyond Metformin: Safety Considerations in the Decision-Making Process for Selecting a Second Medication for Type 2 Diabetes Management Reflections From a Diabetes Care Editors' Expert Forum
William T. Cefalu et al.
DIABETES CARE (2014)
Efficacy and safety of initial combination treatment with sitagliptin and pioglitazone-a factorial study
R. R. Henry et al.
DIABETES OBESITY & METABOLISM (2014)
Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naive patients with type 2 diabetes: a randomized, double-blind, 6-month study
R. E. Pratley et al.
DIABETES OBESITY & METABOLISM (2014)
Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials
Yifei Zhang et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2014)
The effect of alogliptin and pioglitazone combination therapy on various aspects of β-cell function in patients with recent-onset type 2 diabetes
Daniel H. van Raalte et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2014)
Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease
Andre J. Scheen
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2014)
Alogliptin benzoate for the treatment of type 2 diabetes
Yutaka Seino et al.
EXPERT OPINION ON PHARMACOTHERAPY (2014)
Pancreatic Safety of Incretin-Based Drugs - FDA and EMA Assessment
Amy G. Egan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Dipeptidyl peptidase-4 inhibitors and heart failure: A meta-analysis of randomized clinical trials
M. Monami et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2014)
Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies
Ling Li et al.
BMJ-BRITISH MEDICAL JOURNAL (2014)
Effect of Cytochrome P450 2C8*3 on the Population Pharmacokinetics of Pioglitazone in Healthy Caucasian Volunteers
Rajendra Kadam et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2013)
Impact of the CYP2C8*3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone
Christina L. Aquilante et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetics of Empagliflozin and Linagliptin After Coadministration in Healthy Male Volunteers
Christian Friedrich et al.
CLINICAL THERAPEUTICS (2013)
Pioglitazone and Cancer: Angel or Demon?
Michael S. Kostapanos et al.
CURRENT PHARMACEUTICAL DESIGN (2013)
Metformin revisited: A critical review of the benefit-risk balance in at-risk patients with type 2 diabetes
A. J. Scheen et al.
DIABETES & METABOLISM (2013)
Combine and conquer: advantages and disadvantages offixed-dose combination therapy
D. S. H. Bell
DIABETES OBESITY & METABOLISM (2013)
Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials
M. Monami et al.
DIABETES OBESITY & METABOLISM (2013)
Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation
Andre J. Scheen
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2013)
Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis
Andre Scheen
EXPERT OPINION ON DRUG SAFETY (2013)
Cardiovascular effects of gliptins
Andre J. Scheen
NATURE REVIEWS CARDIOLOGY (2013)
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Enhancing Pancreatic Beta-Cell Regeneration In Vivo with Pioglitazone and Alogliptin
Hao Yin et al.
PLOS ONE (2013)
A new Comparative Effectiveness assessment strategy using the THIN database: comparison of the cardiac complications of pioglitazone and rosiglitazone
Richard Tannen et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2013)
Influence of CYP2C8☆2 on the Pharmacokinetics of Pioglitazone in Healthy African-American Volunteers
Christina L. Aquilante et al.
PHARMACOTHERAPY (2013)
SGLT2 versus DPP4 inhibitors for type 2 diabetes
Andre J. Scheen
LANCET DIABETES & ENDOCRINOLOGY (2013)
Fixed-Dose Combination Antidiabetic Therapy: Real-World Factors Associated with Prescribing Choices and Relationship with Patient Satisfaction and Compliance
Mike Benford et al.
ADVANCES IN THERAPY (2012)
Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors
Larry K. Golightly et al.
CLINICAL PHARMACOKINETICS (2012)
Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens: a meta-analysis
Steven Han et al.
CURRENT MEDICAL RESEARCH AND OPINION (2012)
Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study
K. H. Yoon et al.
DIABETES OBESITY & METABOLISM (2012)
Outcomes and lessons from the PROactive study
Andre J. Scheen
DIABETES RESEARCH AND CLINICAL PRACTICE (2012)
Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study
B. Eliasson et al.
DIABETOLOGIA (2012)
Cardiovascular Biology of the Incretin System
John R. Ussher et al.
ENDOCRINE REVIEWS (2012)
Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes
Andre J. Scheen
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2012)
Metformin plus saxagliptin for type 2 diabetes
Andre J. Scheen
EXPERT OPINION ON PHARMACOTHERAPY (2012)
A review of gliptins in 2011
Andre J. Scheen
EXPERT OPINION ON PHARMACOTHERAPY (2012)
Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus
Elisa Guarino et al.
EXPERT OPINION ON PHARMACOTHERAPY (2012)
Efficacy and Tolerability of the DPP-4 Inhibitor Alogliptin Combined with Pioglitazone, in Metformin-Treated Patients with Type 2 Diabetes
R. A. DeFronzo et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Gliptin versus a sulphonylurea as add-on to metformin
Andre J. Scheen et al.
LANCET (2012)
The role of incretins in salt-sensitive hypertension: the potential use of dipeptidyl peptidase-IV inhibitors
Tetsuhiro Tanaka et al.
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION (2011)
Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study
E. Bosi et al.
DIABETES OBESITY & METABOLISM (2011)
Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study
K. Kaku et al.
DIABETES OBESITY & METABOLISM (2011)
Pioglitazone: A Promising Therapeutic Tool in Sodium Taurocholate-Induced Severe Acute Pancreatitis
Ping Xu et al.
DIGESTIVE DISEASES AND SCIENCES (2011)
Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects
A. Karim et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2011)
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes
K. H. Yoon et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2011)
Dipeptidylpeptitase-4 Inhibitors (Gliptins) Focus on Drug-Drug Interactions
Andre J. Scheen
CLINICAL PHARMACOKINETICS (2010)
Initial Combination Therapy With Alogliptin and Pioglitazone in Drug-Naive Patients With Type 2 Diabetes
Julio Rosenstock et al.
DIABETES CARE (2010)
Pharmacokinetics of dipeptidylpeptidase-4 inhibitors
A. J. Scheen
DIABETES OBESITY & METABOLISM (2010)
Alogliptin A Review of its Use in the Management of Type 2 Diabetes Mellitus
Lesley J. Scott
DRUGS (2010)
Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin
Andre J. Scheen
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2010)
Pioglitazone: side effect and safety profile
Priya Shah et al.
EXPERT OPINION ON DRUG SAFETY (2010)
Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone
Clifford J. Bailey et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Pioglitazone Use in Combination with Insulin in the Prospective Pioglitazone Clinical Trial in Macrovascular Events Study (PROactive19)
Bernard Charbonnel et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Addition of incretin therapy to metformin in type 2 diabetes
Andre J. Scheen et al.
LANCET (2010)
DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy
Georgia Argyrakopoulou et al.
ADVANCES IN THERAPY (2009)
Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and β-cell function in db/db mice
Y. Moritoh et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study
Richard E. Pratley et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Thiazolidinediones and the liver in humans
Hannele Yki-Jarvinen
CURRENT OPINION IN LIPIDOLOGY (2009)
From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
Ralph A. DeFronzo
DIABETES (2009)
Fixed-dose single tablet antidiabetic combinations
C. J. Bailey et al.
DIABETES OBESITY & METABOLISM (2009)
Long-term glycaemic control with metformin-sulphonylurea-pioglitazone triple therapy in PROactive (PROactive 17)
A. J. Scheen et al.
DIABETIC MEDICINE (2009)
Long-term glycaemic effects of pioglitazone compared with placebo as add-on treatment to metformin or sulphonylurea monotherapy in PROactive (PROactive 18)
A. J. Scheen et al.
DIABETIC MEDICINE (2009)
The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice
Yusuke Moritoh et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2009)
Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors
G. Schernthaner
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2009)
Coadministration of Pioglitazone or Glyburide and Alogliptin: Pharmacokinetic Drug Interaction Assessment in Healthy Participants
Aziz Karim et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database
Ioanna Tzoulaki et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects
Ronald Christopher et al.
CLINICAL THERAPEUTICS (2008)
Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptino: A randomized, double-mind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes
Paul Covington et al.
CLINICAL THERAPEUTICS (2008)
National Cholesterol Education Program and International Diabetes Federation Definitions of metabolic syndrome in the prediction of diabetes. Results from the Flrenze-Bagno - A Ripoli study
E. Mannucci et al.
DIABETES OBESITY & METABOLISM (2008)
Assessing the cardiovascular safety of diabetes therapies
Allison B. Goldfine
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone
Aleksi Tornio et al.
DRUG METABOLISM AND DISPOSITION (2008)
Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08)
Erland Erdmann et al.
DIABETES CARE (2007)
Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials
Rodrigo M. Lago et al.
LANCET (2007)
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
Steven E. Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Thiazolidinedi ones and their fluid-related adverse effects - Facts, fiction and putative management strategies
Janaka Karalliedde et al.
DRUG SAFETY (2007)
Pharmacokinetic interactions with thiazolidinediones
Andre J. Scheen
CLINICAL PHARMACOKINETICS (2007)
Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro:: Potential for interactions with CYP2C8 inhibitors
Tiina Jaakkola et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2006)
Pioglitazone - A review of its use in type 2 diabetes mellitus
J Waugh et al.
DRUGS (2006)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
JA Dormandy et al.
LANCET (2005)
Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone
T Jaakkola et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Drug therapy: Thiazolidinediones
H Yki-Jarvinen
NEW ENGLAND JOURNAL OF MEDICINE (2004)
The pharmacokinetics of pioglitazone in patients with impaired renal function
K Budde et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Thiazolidinediones in type 2 diabetes mellitus - Current clinical evidence
M Diamant et al.
DRUGS (2003)
Clinical pharmacokinetics of pioglitazone
DA Eckland et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2000)
分享论文
